New drug aims to reverse wasting in cancer patients

NCT ID NCT05865535

Recruiting now Symptom relief Sponsor: AVEO Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests AV-380, an antibody that blocks a protein linked to cancer-related weight loss (cachexia). About 30 adults with advanced solid tumors and high GDF-15 levels will receive AV-380 alongside their standard chemotherapy. The main goal is to check safety and find the right dose.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CACHEXIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cachexia neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CACHEXIA

Contacts and locations

Locations

Advent Health Orlando Hospital
RECRUITING

Orlando, Florida, 32804, United States
Astera Cancer Care
RECRUITING

East Brunswick, New Jersey, 08816, United States
Beverly Hills Cancer Center
RECRUITING

Beverly Hills, California, 90211, United States
Cancer and Blood Specialty Clinic
RECRUITING

Lakewood, California, 90712, United States
Community Clinical Trials
RECRUITING

Kingwood, Texas, 77339, United States
Hartford Hospital
RECRUITING

Hartford, Connecticut, 06102, United States
Hoag Memorial Hospital
RECRUITING

Newport Beach, California, 92663, United States
MUSC Hollings Cancer Center
RECRUITING

Charleston, South Carolina, 29425, United States
Nebraska Cancer Specialists
RECRUITING

Omaha, Nebraska, 68130, United States
New York Cancer And Blood Specialists
RECRUITING

Shirley, New York, 11967, United States
Oregon Health and Science University
RECRUITING

Portland, Oregon, 97239, United States
Vanderbilt University Henry-Joyce Cancer Clinic
RECRUITING

Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.